Latest news

We are pleased to provide a status update on our development of Eribulin injection 0.44mg/ml. The development of this product is progressing very well; our dossier will be available for...

We are pleased to announce that, following the successful completion of our ANDA for Midostaurin Capsules 25mg in the US, we have now completed our Pivotal BE program in Europe....

We are pleased to announce that our US dossier of Semaglutide 1.34mg/ml pre-filled pen is ready and available for licensing in Ex-US markets. We will now move full steam...

Adalvo is delighted to announce that we have successfully completed dossier filing of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. With the present submission, we believe we will be amongst...

Aztiq is thrilled to announce the recent establishment of a new entity Arphio a venture initiated in close collaboration with SK Pharma.

Adalvo is delighted to announce that we have successfully completed our Pivotal BE study of Apixaban 5mg Film Coated Tablets.

Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), a clinical stage company developing innovative stem cell therapies, announced today that the European Commission and the European Medicines...

Adalvo is pleased to announce that we have successfully launched Icatibant in 14 markets. This product is a complex injectable peptide, forming part of our high-value product portfolio offering to...

As this new year begins, Adalvo is delighted to announce that we have successfully completed our Pivotal BE study of Vortioxetine Film-Coated Tablets.

Adalvo is thrilled to announce that we have entered into a strategic collaboration deal with Naari Pharma, a vertically integrated women’s health pharmaceutical business, based in Bangalore, India.

Adalvo is pleased to announce that we have successfully submitted our EU DCP procedure for Nitrofurantoin ER 100mg Capsules, another differentiated product within our portfolio, that was developed based on...

Adalvo, one of the leading B2B global pharmaceutical companies, with commercial partnerships in more than 100 countries, have been certified as one of the Best Places to Work for 2021!...

The Consortium jointly, through Aztiq II HoldCo Limited, will acquire a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholders in Lotus and Adalvo.

We are pleased to announce that our General Manager, Anil Okay has been awarded the Leader of the Year Award 2021, by the Global Generics & Biosimilar Awards committee.

Adalvo is delighted to announce that we successfully completed our Pivotal BE study of Nintedanib 100mg & 150mg soft gel capsules. We are now moving ahead into dossier completion, and...

Adalvo is delighted to announce that we successfully completed our Pivotal BE study of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. We are now moving ahead into dossier completion and...

We are proud to announce the successful submission of our DCP procedure for our distinguished hybrid / 505(b)(2) asset Gralise®. We expect to launch this high- value asset in H1...

We are extremely delighted to announce that we successfully submitted our DCP procedure for Liraglutide 6mg/ml pre-filled pen on Friday 29th October, which has been developed in close...

Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), has been awarded an Innovation Passport for CorLiCyte™, by the UK’s regulatory agencies (MHRA, NICE, SMC), becoming one of...

Adalvo is delighted to announce the successful submission of our DCP procedure for Lisdexamfetamine Oral Solution 10mg / ml which has been developed in close collaboration with Laboserve & Pharma-Data....

Adalvo is pleased to announce the successful closure on our DCP procedure for our Icatibant development, a complex injectable peptide product, forming part of our high-value product portfolio offering to...